 |
|
Dear Reader :
The IPA and Citeline wish you a prosperous New Year and hope you had a joyous, sparkling Diwali!
This month’s edition of our co-developed newsletter features an all-important discussion by global pharma chiefs on pressing issues and potential macro risks industry is faced with.
We also bring you expert opinion on the perils of over-reliance on out-licensing as a growth lever, while another piece highlights why the US FDA is keen that sponsors incorporate ‘resilience’ into clinical trials.
Anju Ghangurde - Executive Editor (Asia Pacific), Scrip/Pink Sheet
Dr. Shridhar Narayanan - Senior Technical Advisor - Innovation, IPA
|
|
|
 |
|
Perspective From Industry Leaders |
|
|
|
|
Licensing & Collaboration Agreements |
|
|
|
|
|
|
|
|
|
|
|
